Bio
-
Labor L+S AG, Symbiosis form alliance
Labor L+S AG, Bad Bocklet and Symbiosis, the newly created business division of Biopharm GmbH, Heidelberg, announced that they have entered into an exclusive business alliance.
Bio | 16 May 2012
-
Quintiles, Biofund to expand clinical development capabilities in Russia
Russian venture company (RVC), Biofund, and Quintiles announced an agreement to support expansion of clinical development services within the Russian Federation, the world’s ninth most populous country.
Bio | 13 April 2012
-
BiotechCorp, Quintiles collaborate
Quintiles solidified the partnership with BiotechCorp, signifying interests in the areas of shared services central laboratory and biobank, clinical research graduate/internship training program, stem cell research and national vaccine hub.
Bio | 02 April 2012
-
Leukocare receives Frost & Sullivan’s biotechnology investment opportunity award
Leukocare has been awarded 2011’s Biotechnology Investment Opportunity Award by Frost & Sullivan.
Bio | 30 March 2012
-
apceth, Indivumed to develop biomarker platform for targeted cellular therapies
apceth and Indivumed have entered into a partnership for the development of a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.
Bio | 27 March 2012
-
JSR expands biomedical business
JSR Corporation and BIA Separations announced that they have entered a partnership which includes a minor equity position by JSR.
Bio | 29 February 2012
-
Biosimilars provide cost saving to users, industry
Biosimilars provide significant cost saving to both the users and the industry hence the adoption of these drugs are expected to be higher side.
Bio | 24 February 2012
-
BiondVax’s universal flu vaccine improves existing flu vaccines in elderly
BiondVax Pharmaceuticals announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly.
Bio | 20 February 2012
-
Novozymes Biopharma wins technology innovation award
Novozymes Biopharma has received the 2012 Drug Delivery Partnerships (DDP) Technology Innovation award for the company’s half-life extension platform. The award recognizes the most exciting delivery technology of the year.
Bio | 08 February 2012
-
MabCure signs license agreement with Biotech Investment Corp
MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.
Bio | 07 February 2012
